Medications: A risk factor for periodontal disease diagnosis and treatment

Journal of Periodontology

Volumn 76, Issue 11 SUPPL., 2005, Pages 2061-2065

  Ciancio, Sebastian G ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Diagnosis; Medications; Periodontal disease; Risk factor; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANGELICA SINENSIS EXTRACT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIPARKINSON AGENT; BARBITURIC ACID DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARICA PAPAYA EXTRACT; CORTICOSTEROID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXYCYCLINE; GARLIC EXTRACT; GINGER EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN V; PHENYLBUTAZONE; PHENYTOIN; SALVIA MILTIORRHIZA EXTRACT; SEDATIVE AGENT; SULFONAMIDE; TETRACYCLINE; UNINDEXED DRUG;

ALVEOLAR BONE; ANAMNESIS; APHTHOUS ULCER; ARTICLE; BONE NECROSIS; DOSE RESPONSE; ERYTHEMA MULTIFORME; GINGIVA BLEEDING; GINGIVA HYPERTROPHY; GINGIVITIS; HUMAN; HYPERPIGMENTATION; LICHENOID ERUPTION; LOW DRUG DOSE; MOUTH HYGIENE; MOUTH MUCOSA; NONHUMAN; OSTEOPOROSIS; PERIODONTAL DISEASE; PREVENTIVE DENTISTRY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; TOOTH PLAQUE; TREATMENT PLANNING; UNITED STATES; XEROSTOMIA;

ADRENAL CORTEX HORMONES; ALVEOLAR BONE LOSS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BONE DENSITY CONSERVATION AGENTS; DRUG UTILIZATION; GINGIVAL OVERGROWTH; HUMANS; MOUTH MUCOSA; PERIODONTAL DISEASES; PHARMACEUTICAL PREPARATIONS; PIGMENTATION DISORDERS; POLYPHARMACY; RISK FACTORS; TETRACYCLINE; XEROSTOMIA;

EID: 28644447592     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2005.76.11-S.2061     Document Type: Article

References (34)

1. Cox H. Later Life, The Realities of Aging, 5th ed. Upper Saddle River, NJ: Prentice Hall; 2001:3.
2. National Center for Chronic Disease Prevention and Health Promotion. Preventing the diseases of aging. In: Chronic Disease Notes & Reports. Atlanta: Centers for Disease Control and Prevention. 1999;12(3):1.
3. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone survey. JAMA 2002;287:337-344.
4. Clark DB. Dental care for the patient with bipolar disorder. J Can Dent Assoc 2003;69:20-24.
5. Butt GM. Drug-induced xerostomia. J Can Den Assoc 1991;57:391-393.
6. Guggenheimer J, Moore PA. Xerostomia. Etiology, recognition and treatment. J Am Dent Assoc 2003; 134:61-69.
7. Nieuw Amerongen AV, Veerman ECI. Saliva - the defender of the oral cavity. Oral Dis 2002;8:12-22.
8. Streckfus CF, Strahl RC, Welsh S. Anti-hypertension medications. An epidemiological factor in the prevalence of root decay among geriatric patients suffering from hypertension. Clin Prev Dent 1990;12:26-29.
9. McClain DL, Bader JD, Daniel SJ, Sams DH. Gingival effects of prescription medications among adult dental patients. Spec Care Dent 1991;11:15-18.
10. Keller S, Frishman WH. Neuropsychiatric effects of cardiovascular drug therapy. Cardiol Rev 2003;11:73-93.
11. Royzman D, Recio L, Badovinac RL, et al. The effect of aspirin intake on bleeding on probing in patients with gingivitis. J Periodontol 2004;75:679-684.
12. Ciancio SG. Herbal agents and oral health. Biologic Ther Dent 2002;18:1-2.
13. Ciancio SG. Medications' impact on oral health. J Am Dent Assoc 2004;135:1440-1448.
14. Byrne BE. Oral manifestations of systemic agents. In: Ciancio SG, ed. ADA Guide to Dental Therapeutics, 3rd ed. Chicago: ADA Publishing Company; 2003: 517-518.
15. Ziskin DE, Stowe LR, Zegarelli EV. Dilantin hyperplastic gingivitis I. Its cause and treatment. II. Differential appraisal. Am J Orthod Oral Surg 1941;27:350-363.
16. Baden E. Sodium dilantin gingival hyperplasia and conservative treatment: A case report. J Dent Med 1950;5:46-52.
17. Ciancio SG, Yaffe SJ, Catz CC. Gingival hyperplasia and diphenylhydantoin. JPeriodontol 1972;43:411-414.
18. Hall WB. Dilantin hyperplasia: A preventable lesion. J Periodontal Res 1969;4:36-37.
19. Nishikawa S, Tada H, Hamasaki A, et al. Nifedipine-induced gingival hyperplasia: A clinical and in vitro study. J Periodontol 1991;62:30-35.
20. Nuki K, Cooper SH. The role of inflammation in the pathogenesis of gingival enlargement during the administration of diphenylhydantoin sodium in cats. J Periodontal Res 1972;7:102-110.
21. Stone C, Eshenaur A, Hassell T. Gingival enlargement in cyclosporine-treated multiple sclerosis patients. J Dent Res 1989;68 (Spec. Issue):285(Abstr. 831).
22. Hasan AA, Ciancio S. Relationship between amphetamine ingestion and gingival enlargement. Pediatr Dent 2004;26:396-400.
23. Qannam AA. The association between recurrent aphthous ulcers (RAU) and the intake of non-steroidal anti-inflammatory drugs. [Thesis]. Buffalo, NY: University at Buffalo; 2003.
24. Poliak SG, DiGiovanna JJ, Gross EG, Gantt G, Peck GL. Minocycline-associated tooth discoloration in young adults. JAMA 1985;254:2930-2932.
25. Kribbs PK, Chesnut CH, Ott SM, Kilcoyne RF. Relationships between mandibular and skeletal bone in an osteoporotic population. J Prosthet Dent 1989;62: 703-707.
26. Farhat G, Yamout B, Mikati MA, Demirijian S, Sawaya R, El-Hajj F. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58: 1348-1353.
27. Caton JG, Ciancio SG, Blieden TM, et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol 2000;71:521-532.
28. Ciancio SG, Genco RJ. The use of antibiotics in peridontal disease. Int J Periodontics Restorative Dent 1983;3(6):54-71.
29. Williams RC, Jeffcoat MK, Howell TH, et al. Altering the progression of human alveolar bone loss with the non-steroidal anti-inflammatory drug flurbiprofen. J Periodontol 1989;60:485-490.
30. Feldman RS, Szeto B, Chauncey HH, Goldhaber P. Non-steroidal anti-inflammatory drugs in the reduction of human alveolar bone loss. J Clin Periodontol 1983;10:131-136.
31. Geurs NC, Lewis CE, Jeffcoat MK. Osteoporosis and penodontal disease progression. Periodontol 2000 2003;32:105-110.
32. Ruggiero SL, Mehrotra B, Rosenbert TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
33. Narai S, Nagahata S. Effects of alendronate on the removal torque of implants in rats with induced osteoporosis. Int J Oral Maxillofac Implants 2003;18: 218-223.
34. Starck WJ, Epker BN. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: A case report. Int J Oral Maxillofac Implants 1995;10:74-78.